Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Website: senseibio.com


  • Bad financial results growth rate 0.0% (average between last period year over year growth for revenue and EBITDA), are preserved at an average historical level (0.0%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -10.9% (LTM)
  • Share price is 3 422.7% higher than minimum and 42.1% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)
  • For the last 3 months insiders sold company shares on $0.6 mln (-0.222% of cap.)

Key Financials (Download financials)

Ticker: SNSE
Share price, USD:  (0.0%)10.17
year average price 6.18  


year start price 0.48 2025-02-14

min close price 0.29 2025-04-04

max close price 17.58 2025-10-16

current price 10.17 2026-02-13
Common stocks: 25 192 363

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 256
Net Debt ($m): -7
EV (Enterprise Value): 249
EBITDA LTM (млн $): -40
Price to Book: 11.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-13globenewswire.com

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

2025-02-06zacks.com

What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock

2024-11-14globenewswire.com

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

2024-10-29globenewswire.com

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

2024-08-06globenewswire.com

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

2024-05-24investorplace.com

Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?

2024-05-23globenewswire.com

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

2023-10-25GlobeNewsWire

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

2023-04-13GlobeNewsWire

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q1 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31 2021-12-31 2020-12-31
symbol SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-14 2025-08-05 2024-11-14 2024-08-06 2024-05-09 2023-11-07 2023-08-03 2023-05-09 2022-11-08 2022-05-10
acceptedDate 2025-11-14 07:45:45 2025-08-05 16:30:52 2025-03-28 07:45:31 2024-11-14 08:03:11 2024-08-06 16:30:28 2024-05-09 16:31:15 2024-02-29 16:30:47 2023-11-07 16:40:31 2023-08-03 16:32:37 2023-05-09 16:32:51 2023-03-29 07:31:10 2022-11-08 16:32:30 2022-05-10 17:03:09 2022-03-15 07:01:25 2021-03-30 06:15:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q1 FY FY
revenue -5M 0 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue -5M 37 000 551 000 0 135 000 137 000 571 000 455 000 491 000 0 2M 0 0 685 000 209 000
grossProfit 0 -37 000 -551 000 0 -135 000 -137 000 -571 000 -455 000 -491 000 0 -2M 0 0 -685 000 -209 000
grossProfitRatio 0 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 3M 3M 19M 5M 5M 5M 18M 4M 5M 5M 30M 9M 7M 22M 12M
generalAndAdministrativeExpenses 2M 0 0 3M 3M 4M 19M 4M 5M 6M 0 5M 5M 0 8M
sellingAndMarketingExpenses 0 0 0 0 0 -137 000 100 000 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 3M 12M 3M 3M 4M 19M 4M 5M 6M 18M 5M 5M 15M 8M
otherExpenses 0 0 0 0 0 -2000 -571 000 613 000 68 000 831 000 0 0 0 0 -209 000
operatingExpenses 5M 5M 31M 8M 8M 9M 36M 8M 10M 11M 47M 14M 12M 37M 19M
costAndExpenses 0 5M 32M 8M 8M 9M 37M 8M 10M 11M 49M 14M 12M 37M 19M
interestIncome 289 000 321 000 3M 591 000 669 000 768 000 4M 877 000 952 000 969 000 2M 515 000 310 000 800 000 1689
interestExpense 6000 10000 90 000 21 000 24 000 28 000 144 000 33 000 38 000 42 000 219 000 10000 243 000 670 000 2M
depreciationAndAmortization 34 000 37 000 551 000 332 000 328 000 137 000 4M 332 000 332 000 358 000 2M 877 000 334 000 685 000 209 000
ebitda -5M -5M -30M -7M -7M -9M -33M -8M -9M -11M -47M -13M -12M -35M -18M
ebitdaratio 0.934 0 0 0 0 0 0 0 0 0
operatingIncome -5M -5M -32M -8M -8M -9M -37M -8M -10M -11M -49M -14M -12M -37M -19M
operatingIncomeRatio 1 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 282 000 270 000 2M 570 000 645 000 738 000 3M 613 000 -123 000 831 000 532 000 525 000 82 000 688 000 -649 000
incomeBeforeTax -5M -5M -30M -7M -7M -8M -34M -7M -9M -10M -49M -13M -12M -37M -20M
incomeBeforeTaxRatio 0.942 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 0 0 0 93 724 0 -332 000 106 000 -1M 0 -525 000 0 0 0
netIncome -5M -5M -30M -7M -7M -8M -34M -7M -9M -9M -49M -13M -12M -37M -20M
netIncomeRatio 0.942 0 0 0 0 0 0 0 0 0
eps -3.62 -3.91 -1.2 -0.29 -0.28 -0.32 -1.22 -0.28 -0.31 -0.29 -1.58 -0.42 -0.4 -1.33 -0.67
epsdiluted -3.62 -3.91 -0.29 -0.28 -0.32 -0.28 -0.31 -0.29 -0.42 -0.4
weightedAverageShsOut 1M 1M 25M 25M 25M 25M 28M 26M 31M 31M 31M 31M 31M 28M 31M
weightedAverageShsOutDil 1M 1M 25M 25M 25M 25M 28M 26M 31M 31M 31M 31M 31M 28M 31M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-28 2024-02-29 2023-03-29 2022-03-15 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 2M 3M 2M 130 000 -2M
ebit -30M -37M -48M -36M -18M
nonOperatingIncomeExcludingInterest -2M -100 000 -750 999 -1M -1M
netIncomeFromContinuingOperations -30M -34M -49M -37M -20M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -30M -34M -49M -37M -20M
epsDiluted -1.2 -1.22 -1.58 -1.33 -0.67

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q1 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31 2021-12-31 2020-12-31
symbol SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-14 2025-08-05 2024-11-14 2024-08-06 2024-05-09 2023-11-07 2023-08-03 2023-05-09 2022-11-08 2022-05-10
acceptedDate 2025-11-14 07:45:45 2025-08-05 16:30:52 2025-03-28 07:45:31 2024-11-14 08:03:11 2024-08-06 16:30:28 2024-05-09 16:31:15 2024-02-29 16:30:47 2023-11-07 16:40:31 2023-08-03 16:32:37 2023-05-09 16:32:51 2023-03-29 07:31:10 2022-11-08 16:32:30 2022-05-10 17:03:09 2022-03-15 07:01:25 2021-03-30 06:15:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q1 FY FY
cashAndCashEquivalents 11M 13M 10M 19M 12M 11M 13M 11M 10M 8M 18M 11M 9M 7M 17M
shortTermInvestments 14M 16M 31M 28M 40M 47M 53M 61M 69M 87M 89M 105M 128M 140M 0
cashAndShortTermInvestments 25M 29M 41M 47M 52M 58M 66M 72M 79M 8M 107M 117M 136M 148M 17M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 744 000 944 000 120 000 1M 2M 2M 325 000 318 000 252 000 454 000 344 000 336 000 3M 374 000 2M
totalCurrentAssets 26M 30M 42M 48M 54M 60M 67M 72M 81M 99M 109M 118M 139M 149M 20M
propertyPlantEquipmentNet 2M 2M 3M 5M 6M 6M 7M 8M 8M 9M 10M 10M 11M 5M 1M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 18 000 24 000 48 000 87 000 87 000 85 999 86 000 2M 86 000 81 000 63 000 45 000 39 000 39 000 86 000
totalNonCurrentAssets 2M 2M 3M 5M 6M 6M 7M 10M 9M 9M 10M 10M 11M 5M 1M
otherAssets 0 0 0 0 0 0 0 0 0 0 -1000 0 0 0 0
totalAssets 28M 32M 45M 53M 60M 67M 74M 82M 90M 108M 118M 129M 150M 153M 21M
accountPayables 0 351 000 1M 0 2M 2M 2M 3M 2M 0 4M 5M 0 2M 4M
shortTermDebt 2M 2M 2M 2M 5M 2M 0 2M 2M 2M 0 2M 2M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 -3M -2M 0 0 0 0 0 0
otherCurrentLiabilities 3M 2M 0 3M -2M 514 000 0 4M 3M 5M 0 2M 6M 0 0
totalCurrentLiabilities 4M 4M 5M 5M 5M 5M 6M 6M 5M 8M 9M 8M 8M 5M 5M
longTermDebt 146 000 596 000 0 2M 3M 3M 0 4M 5M 5M 0 6M 7M 0 567 000
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 67 000 68 000 67 000 67 000 72 000 34 000 0 -405 000 0 149 000 52 000
totalNonCurrentLiabilities 146 000 596 000 2M 2M 3M 3M 4M 4M 5M 6M 6M 6M 7M 2M 705 000
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 596 000 2M 4M 5M 3M 6M 7M 7M 8M 8M 8M 9M 2M 118 000
totalLiabilities 5M 4M 7M 7M 8M 8M 9M 11M 10M 13M 15M 15M 15M 7M 6M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 72M
commonStock 0 0 3000 3000 3000 3000 3000 2000 3000 3000 3000 3000 3000 3000 0
retainedEarnings -278M -274M -262M -254M -247M -240M -232M -224M -217M -208M -198M -186M -162M -149M -112M
accumulatedOtherComprehensiveIncomeLoss -3000 -11 000 -13 000 14 000 -93 000 -137 000 -209 000 -402 000 -549 000 -823 000 -1M -1M -899 000 -333 000 0
othertotalStockholdersEquity 301M 301M 300M 299M 298M 296M 297M 304M 301M 298M
totalStockholdersEquity 23M 27M 38M 46M 52M 58M 65M 71M 79M 95M 103M 114M 135M 147M 16M
totalEquity 23M 27M 38M 46M 52M 58M 65M 71M 79M 95M 103M 114M 135M 147M 16M
totalLiabilitiesAndStockholdersEquity 28M 32M 53M 60M 67M 82M 90M 108M 129M 150M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 28M 32M 45M 53M 60M 67M 74M 82M 90M 108M 118M 129M 150M 153M 21M
totalInvestments 0 16M 31M 28M 40M 47M 53M 61M 69M 87M 89M 105M 0 140M 0
totalDebt 2M 3M 4M 4M 5M 6M 6M 7M 7M 8M 8M 8M 9M 2M 685 000
netDebt -9M -10M -6M -15M -7M -5M -7M -5M -3M -358 000 -10M -3M 349 000 -5M -16M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-28 2024-02-29 2023-03-29 2022-03-15 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 474 000 1M 1M 547 000 1M
totalPayables 1M 2M 4M 2M 4M
otherPayables 0 0 0 0 0
accruedExpenses 2M 2M 2M 2M 916 000
capitalLeaseObligationsCurrent 0 2M 2M 680 000 32 000
capitalLeaseObligationsNonCurrent 2M 4M 6M 2M 86 000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 300M 297M 302M 296M 56M
otherTotalStockholdersEquity 0 0 0 -0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q1 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31 2021-12-31 2020-12-31
symbol SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE SNSE
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-14 2025-08-05 2024-11-14 2024-08-06 2024-05-09 2023-11-07 2023-08-03 2023-05-09 2022-11-08 2022-05-10
acceptedDate 2025-11-14 07:45:45 2025-08-05 16:30:52 2025-03-28 07:45:31 2024-11-14 08:03:11 2024-08-06 16:30:28 2024-05-09 16:31:15 2024-02-29 16:30:47 2023-11-07 16:40:31 2023-08-03 16:32:37 2023-05-09 16:32:51 2023-03-29 07:31:10 2022-11-08 16:32:30 2022-05-10 17:03:09 2022-03-15 07:01:25 2021-03-30 06:15:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q1 FY FY
netIncome -5M -5M -30M -7M -7M -8M -34M -7M -9M -10M -49M -13M -12M -37M -20M
depreciationAndAmortization 34 000 37 000 1M 854 000 0 137 000 1M 332 000 332 000 358 000 1M 342 000 334 000 685 000 209 000
deferredIncomeTax 0 0 0 0 0 0 0 -214 000 -142 000 0 0 0 0 19 000 0
stockBasedCompensation 254 000 264 000 3M 733 000 795 000 1M 4M 1M 1M 1M 6M 1M 2M 6M 1M
changeInWorkingCapital 2M -1M -489 000 1M 85 000 -1M -4M 979 000 -2M -3M 1M 5M -667 000 117 000 -397 000
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables -953 000 -1M -445 000 -324 000 0 306 000 -2M 471 000 -2M 242 000 2M 0 0 -1M 335 000
otherWorkingCapital 3M -266 000 -44 000 2M 85 000 -2M -2M 508 000 548 000 -3M -1M 5M -1M 2M -732 000
otherNonCashItems -2M 214 000 2M -1M 470 000 2M 603 000 318 000 353 000 64 000 1M 247 000 473 000 57 000 1M
netCashProvidedByOperatingActivities -4M -6M -25M -5M -6M -8M -32M -5M -9M -12M -39M -7M -11M -30M -18M
investmentsInPropertyPlantAndEquipment 0 -16 000 -146 000 0 -109 000 -37 000 -180 000 0 -29 000 -151 000 -321 000 -250 000 -19 000 -2M -1M
acquisitionsNet -40 000 210 000 0 0 0 0 166 000 0 157 000 0 15 000 0 0 318 000 -197 000
purchasesOfInvestments -10M -2M -45M -9M -12M -6M -21M -9M -2000 -10M -47M -22M -8M -184M 0
salesMaturitiesOfInvestments 12M 11M 67M 22M 19M 12M 60M 17M 19M 12M 97M 31M 20M 42M 0
otherInvestingActivites 40 000 0 0 0 5807 8312 0 9000 15 000 0
netCashUsedForInvestingActivites 2M 9M 13M 7M 6M 8M 20M 2M 9M 12M
debtRepayment 0 -314 000 -204 000 -201 000 -199 000 -190 000 -189 000 -186 000 -163 000 -133 000
commonStockIssued 0 5000 0 0 0 0 0 0 0 0
commonStockRepurchased 0 0 0 10 0 -10 -10M -2M -8M 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -152 000 141 000 0 21 000 -10000 -10 132 31 000 -76 000 0 252 000
netCashUsedProvidedByFinancingActivities -152 000 -168 000 -204 000 -180 000 -209 000 -3M -8M -262 000 -163 000 119 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 -12M 0 0 0 0 0 0
netChangeInCash -2M 3M -3M 7M 935 000 -2M -5M 1M 2M -10M 11M 2M 2M -9M 16M
cashAtEndOfPeriod 11M 13M 10M 19M 12M 11M 13M 11M 10M 8M 18M 11M 9M 7M 17M
cashAtBeginningOfPeriod 13M 10M 13M 12M 11M 13M 18M 10M 8M 18M 7M 10M 7M 17M 251 000
operatingCashFlow -4M -6M -25M -5M -6M -8M -32M -5M -9M -12M -39M -7M -11M -30M -18M
capitalExpenditure 0 -16 000 -146 000 0 -109 000 -37 000 -180 000 0 -29 000 -151 000 -321 000 -250 000 -19 000 -2M -1M
freeCashFlow -4M -6M -25M -5M -6M -8M -32M -5M -9M -12M -39M -7M -11M -32M -19M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-28 2024-02-29 2023-03-29 2022-03-15 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities 22M 38M 50M -143M -1M
netDebtIssuance -811 000 -761 000 -629 000 -255 000 526 000
longTermNetDebtIssuance -811 000 -761 000 -629 000 -255 000 526 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 34 000 -10M 342 000 164M 37M
netCommonStockIssuance 34 000 -10M 342 000 141M 0
commonStockIssuance 34 000 48 000 342 000 141M 0
netPreferredStockIssuance 0 48 000 0 23M 37M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -10000 -76 000 0 109 000 -2M
netCashProvidedByFinancingActivities -787 000 -11M -287 000 164M 35M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 12 000

Earning call transcript

SEC forms

Show financial reports only

SEC form 10
2025-11-14 07:45 ET
Sensei Biotherapeutics, Inc. reported for 2025 q3
SEC form 8
2025-11-14 07:35 ET
Sensei Biotherapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-14 07:35 ET
Sensei Biotherapeutics, Inc. published news for 2025 q3
SEC form 8
2025-10-30 13:05 ET
Sensei Biotherapeutics, Inc. published news for 2025 q3
SEC form 8
2025-10-30 13:05 ET
Sensei Biotherapeutics, Inc. published news for 2025 q3
SEC form 8
2025-10-17 12:05 ET
Sensei Biotherapeutics, Inc. published news for 2025 q3
SEC form 8
2025-10-17 12:05 ET
Sensei Biotherapeutics, Inc. published news for 2025 q3
SEC form 8
2025-10-17 12:05 ET
Sensei Biotherapeutics, Inc. published news for 2025 q3
SEC form 10
2025-08-05 20:30 ET
Sensei Biotherapeutics, Inc. reported for 2025 q2
SEC form 8
2025-08-05 11:31 ET
Sensei Biotherapeutics, Inc. published news for 2025 q2
SEC form 8
2025-08-05 11:31 ET
Sensei Biotherapeutics, Inc. published news for 2025 q2
SEC form 8
2025-06-13 11:33 ET
Sensei Biotherapeutics, Inc. published news for 2025 q1
SEC form 8
2025-06-13 11:33 ET
Sensei Biotherapeutics, Inc. published news for 2025 q1
SEC form 10
2025-05-06 20:30 ET
Sensei Biotherapeutics, Inc. reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2025 q1
SEC form 8
2025-05-06 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2025 q1
SEC form 8
2025-05-06 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2025 q1
SEC form 10
2025-03-28 07:45 ET
Sensei Biotherapeutics, Inc. reported for 2024 q4
SEC form 8
2025-03-28 07:36 ET
Sensei Biotherapeutics, Inc. published news for 2024 q4
SEC form 8
2025-03-28 07:36 ET
Sensei Biotherapeutics, Inc. published news for 2024 q4
SEC form 10
2025-03-28 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2024 q4
SEC form 8
2025-03-27 21:20 ET
Sensei Biotherapeutics, Inc. published news for 2024 q4
SEC form 8
2025-03-27 21:20 ET
Sensei Biotherapeutics, Inc. published news for 2024 q4
SEC form 8
2025-03-27 21:20 ET
Sensei Biotherapeutics, Inc. published news for 2024 q4
SEC form 10
2024-11-14 08:03 ET
Sensei Biotherapeutics, Inc. reported for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2024 q3
SEC form 8
2024-11-14 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2024 q3
SEC form 8
2024-11-14 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2024 q3
SEC form 10
2024-08-06 16:30 ET
Sensei Biotherapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-06 07:36 ET
Sensei Biotherapeutics, Inc. published news for 2024 q2
SEC form 8
2024-08-06 07:36 ET
Sensei Biotherapeutics, Inc. published news for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2024 q1
SEC form 10
2024-02-29 16:30 ET
Sensei Biotherapeutics, Inc. reported for 2023 q4
SEC form 10
2024-02-29 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q4
SEC form 8
2024-02-28 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2023 q4
SEC form 8
2024-02-28 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2023 q4
SEC form 10
2023-11-07 16:40 ET
Sensei Biotherapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-07 07:35 ET
Sensei Biotherapeutics, Inc. published news for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-03 16:32 ET
Sensei Biotherapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-03 08:45 ET
Sensei Biotherapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q2
SEC form 6
2023-07-10 16:31 ET
Sensei Biotherapeutics, Inc. published news for 2023 q2
SEC form 6
2023-06-27 09:00 ET
Sensei Biotherapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-23 16:30 ET
Sensei Biotherapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-15 16:31 ET
Sensei Biotherapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2023 q1
SEC form 10
2023-03-29 07:31 ET
Sensei Biotherapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-29 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-28 08:26 ET
Sensei Biotherapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-28 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-13 07:31 ET
Sensei Biotherapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-10 09:29 ET
Sensei Biotherapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-07 17:30 ET
Sensei Biotherapeutics, Inc. published news for 2022 q4
SEC form 6
2023-02-06 07:30 ET
Sensei Biotherapeutics, Inc. published news for 2022 q4
SEC form 6
2022-12-09 16:31 ET
Sensei Biotherapeutics, Inc. published news for 2022 q3
SEC form 6
2022-12-08 08:18 ET
Sensei Biotherapeutics, Inc. published news for 2022 q3
SEC form 6
2022-11-10 09:05 ET
Sensei Biotherapeutics, Inc. published news for 2022 q3
SEC form 10
2022-11-08 16:32 ET
Sensei Biotherapeutics, Inc. reported for 2022 q3
SEC form 6
2022-11-08 08:08 ET
Sensei Biotherapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q3
SEC form 6
2022-09-30 16:31 ET
Sensei Biotherapeutics, Inc. published news for 2022 q2
SEC form 6
2022-08-31 07:57 ET
Sensei Biotherapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-09 17:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q2
SEC form 6
2022-08-09 07:46 ET
Sensei Biotherapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q2
SEC form 6
2022-06-14 16:27 ET
Sensei Biotherapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-10 17:03 ET
Sensei Biotherapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-10 07:39 ET
Sensei Biotherapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Sensei Biotherapeutics, Inc. reported for 2022 q1
SEC form 6
2022-04-28 16:13 ET
Sensei Biotherapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-20 08:06 ET
Sensei Biotherapeutics, Inc. published news for 2022 q1
SEC form 10
2022-03-15 07:01 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-15 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-10 08:15 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 8
2022-03-10 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-09 16:23 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 6
2022-01-10 08:32 ET
Sensei Biotherapeutics, Inc. published news for 2021 q4
SEC form 6
2021-12-06 08:32 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-16 16:03 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 17:02 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-09 09:23 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q3
SEC form 6
2021-09-08 08:01 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-11 16:12 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-11 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-04 08:30 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-02 16:15 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-02 08:15 ET
Sensei Biotherapeutics, Inc. published news for 2021 q2
SEC form 6
2021-06-28 16:10 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-17 16:05 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 10
2021-05-13 16:19 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 6
2021-05-12 08:20 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 6
2021-05-03 06:33 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 6
2021-04-05 08:50 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 6
2021-04-05 08:15 ET
Sensei Biotherapeutics, Inc. published news for 2021 q1
SEC form 10
2021-03-30 06:15 ET
Sensei Biotherapeutics, Inc. published news for 2020 q4
SEC form 6
2021-03-25 08:50 ET
Sensei Biotherapeutics, Inc. published news for 2020 q4
SEC form 6
2021-02-11 07:00 ET
Sensei Biotherapeutics, Inc. published news for 2020 q4
SEC form 6
2021-02-03 20:56 ET
Sensei Biotherapeutics, Inc. published news for 2020 q4